Hot Investor Mandate 4: Health Investment Firm Looks Opportunistically for Biotech and Medtech Innovation

10 Nov

An investment firm based in China is focused on medical and health industry investments. The fund is currently investing from its RMB 687 million (USD 100 million) fund. Typical allocation ranges from USD 2 -20 million in companies from Angel, Series A to Pre-IPO rounds. The firm has invested in 12 companies – 5 in medical devices, 6 in biotech and pharma, and 1 in online education. The firm is seeking opportunities from across the world with a focus on China, USA, and Israel.

The firm is opportunistic across sectors including biotechnology and pharmaceutical, medical devices, mobile medical technologies and medical services. The fund is stage agnostic.

The firm is looking for experienced teams with passion and competence, who can deliver innovative, advanced, and market-oriented technology with huge business potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: